[A25-151] Durvalumab (urothelial carcinoma) – Addendum to Project A25-97
Last updated 22.01.2026
Project no.:
A25-151
Commission:
Commission awarded on 09.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with resectable muscle-invasive bladder cancer (MIBC) for whom platinum-based chemotherapy is suitable; neoadjuvant and adjuvant therapy after radical cystectomy
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-151
| Project no. | Title | Status |
|---|---|---|
| A25-97 | Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
22-01-2026 A G-BA decision was published.
G-BA documents on this decision